pipelin driver acceler pt
messag report financi result provid pipelin updat
revenu beat higher takeda mileston payment adcetri miss
consensu estim season accord manag re-affirmed
guidanc continu execut well late stage pipelin program one
pivot trial complet two other fulli enrol result like
updat estim reflect financi result lower pt
revenu beat higher takeda mileston payment adcetri miss
season accord manag report total revenu
street consensu larg driven higher expect collaboration/
licens revenu takeda tak mileston eu-approv adcetri line
hl partial off-set lower consensu adcetri product sale came
street estim adcetri sale grew year-over-year vs
growth vs manag attribut typic
season purchas pattern januari indic sequenti growth februari
march april re-affirmed adcetri product sale guidanc
remain confid adcetri main growth driver line hodgkin lymphoma hl
peripher cell lymphoma indic given increas promot effort
also recent updat nccn treatment guidelin chl also increas
sg expens guidanc reflect posit result pivot trial
enfortumab vedotin bladder cancer link
continu strong execut late stage pipelin one pivot trial complet
two other fulli enrol
full result pivot trial enfortumab vedotin ev
present see planner link manag guid bla
file year base prior deep-div link kol call link think top-lin
data justifi rapid fda-approv rapid commerci uptak ev bladder cancer
repres us opportun base estim result
trial line muc patient could potenti support go-
decis phase trial line muc combin checkpoint inhibitor
significantli increas ev commerci potenti bull-cas scenario
view
tisotumab vedotin tv pivot trial complet enrol march previous
announc complet enrol potenti pivot phase ii innovatv
studi evalu tv monotherapi patient recurr metastat cervic
cancer mcc base phase ib dor result present previous esmo
see comment sgo think top-lin result could potenti
avail late support registr beyond mcc also conduct
phase ii studi platinum-resist ovarian cancer innovatv phase ii
basket trial evalu tv number solid tumor express tissu factor innovatv
expand tucatinib phase trial complet enrol
patient top-lin result guid recal phase ii
pivot random studi evalu tucatinib combin xeloda herceptin
metastat breast cancer mbc patient expand number
patient enrol increas power key secondari endpoint
includ overal surviv os patient brain metastasi could
strengthen potenti product label view kol spoke recent believ
page analyst certif import disclosur
tucatinib promis kinas inhibitor clinic develop given
high thu reduc potenti gi toxic abil cross
blood-brain barrier henc potenti enabl treatment patient
updat collabor earli program bla polatuzumab vedotin
dlbcl submit partner roch rog vx nc
pdufa date august belantamab mafodotin anti-bcma current
develop partner gsk multipl myeloma regulatori submiss
plan phase trial depatuxizumab mafodotin anti-egfr
collabor on-going data expect also announc
compani expect initi phase studi novel anti-
multipl solid tumor year
updat estim pt previous updat estim
reflect financi result updat guidanc also lower adcetri
forecast reflect slower uptak line hl line vs prior assumpt
also increas approv probabl assumpt ev base
recent report top-lin result also increas approv probabl
assumpt tv follow complet trial enrol higher
convict success probabl program
page analyst certif import disclosur
valuat risk
valu previous per share use dcf-base valuat method
reduc sale forecast adcetri slightli increas near-term
sg cost also increas po ev tv recent
reflect increas confid two program recent data mention
valuat includ commerci product adcetri well probability-adjust cash flow deriv
compani pipelin use discount rate consist
commerci stage biotech compani coverag termin growth rate appli
termin year post-assum adcetri biosimilar entri
risk valuat includ regulatori commerci setback potenti
emerg new competitor /or lower product sale expect risk intellectu
properti risk manag execut misstep
page analyst certif import disclosur
royalti revenu
total cost expens
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
royalti revenu
total cost expens
invest incom loss net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
